Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.
Meltzer E, Sguigna PV, Subei A, Beh S, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman EM. Meltzer E, et al. Among authors: sguigna pv. JAMA Neurol. 2017 May 1;74(5):574-582. doi: 10.1001/jamaneurol.2016.5131. JAMA Neurol. 2017. PMID: 28135360 Free PMC article.
Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study.
Sguigna PV, Toranian S, Tardo LM, Blackburn KM, Horton LA, Conger D, Meltzer E, Hogan RN, McCreary MC, Zee PC, Takahashi JS, Greenberg BM. Sguigna PV, et al. Mult Scler J Exp Transl Clin. 2023 Mar 15;9(1):20552173231159560. doi: 10.1177/20552173231159560. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36936446 Free PMC article.
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: sguigna pv. J Nanobiotechnology. 2023 Dec 13;21(1):478. doi: 10.1186/s12951-023-02236-z. J Nanobiotechnology. 2023. PMID: 38087362 Free PMC article. Clinical Trial.
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: sguigna pv. J Nanobiotechnology. 2024 Jan 3;22(1):16. doi: 10.1186/s12951-023-02269-4. J Nanobiotechnology. 2024. PMID: 38167088 Free PMC article. No abstract available.
23 results